Arsil%25252525252525252525252525252525252525252525252525252525252525252525252525252525252520dx

# Arsil (Artemether/Lumefantrine) ## Overview Arsil is a fixed-dose combination antimalarial consisting of artemether (an artemisinin derivative) and lumefantrine (an aryl-amino alcohol). It works by inhibiting nucleic acid and protein synthesis within the *Plasmodium* parasite. ## Primary Indications Treatment of acute, uncomplicated *Plasmodium falciparum* malaria or mixed infections, including infections with *P. falciparum* that may be resistant to other antimalarials. ## Adult Dosing Standard regimen is six doses administered over 3 days (at 0, 8, 24, 36, 48, and 60 hours). * **Weight ≥35 kg:** 4 tablets (20 mg/120 mg per tablet) per dose. * **Total treatment course:** 24 tablets. ## Pediatric Dosing Weight-based dosing (20 mg/120 mg tablets): * **5 kg to <15 kg:** 1 tablet per dose (6 doses total). * **15 kg to <25 kg:** 2 tablets per dose (6 doses total). * **25 kg to <35 kg:** 3 tablets per dose (6 doses total). ## Dose Adjustments * **Renal/Hepatic Impairment:** No specific guidelines provided; use with caution in severe impairment as lumefantrine is metabolized in the liver. * **Vomiting:** If the patient vomits within 30 minutes of taking a dose, readminister the full dose. If vomited within 30 to 60 minutes, administer half a dose. ## Contraindications * Known hypersensitivity to artemether or lumefantrine. * Severe malaria (based on WHO criteria). * History of QT prolongation or congenital long QT syndrome. * Concomitant use of drugs that prolong the QT interval (e.g., flecainide, amiodarone, erythromycin, antipsychotics). ## Adverse Effects * Common: Headache, dizziness, anorexia, fatigue, arthralgia, myalgia, and sleep disorders. * Serious: QT interval prolongation (potentially leading to torsades de pointes), hypersensitivity reactions, and rare cases of late-onset hemolysis. ## Key Drug Interactions * **QT Prolonging Agents:** Absolute contraindication due to synergistic additive effects on cardiac repolarization. * **CYP3A4 Inhibitors/Inducers:** Strongly inhibit or induce the metabolism of both components; adjust/monitor therapy if co-administration is unavoidable. * **Hormonal Contraceptives:** May decrease steady-state concentrations of oral contraceptives; advise use of backup barrier birth control. ## Monitoring * **Cardiac:** EKG monitoring is recommended in patients prone to cardiac conduction abnormalities or those with electrolyte disturbances (hypokalemia/hypomagnesemia). * **Clinical:** Monitor for signs of treatment failure (persisting fever, parasitemia after 72 hours). ## Clinical Pearls * **Administration:** **Crucial:** Must be taken with high-fat food (e.g., milk, porridge) to ensure adequate absorption of lumefantrine. Without fat, efficacy is significantly reduced due to low bioavailability. * **Efficacy:** Highly effective, but not indicated for malaria prophylaxis. * **Protocol Variance:** Local resistance patterns and regional public health guidelines vary significantly. Always verify against local Ministry of Health or CDC malaria clinical guidelines. *** *Disclaimer: This information is for educational purposes only. Always consult the most recent product labeling (package insert) and clinical guidelines before prescribing or administering medication. Dosage protocols may vary by weight, severity of infection, and local resistance patterns.*